Healthcare
Rezolute, Inc.(RZLT)
Live Price
Offline$5.02
+4.80% today
1Y Change
-0.74%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $320.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +26.3%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rezolute, Inc. (RZLT) is a Healthcare stock with a market cap of $320.00M and listed on NASDAQ. The stock last traded around $5.02 and down 0.7% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +26.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +26.3%, free cash flow -20.4% with operating margin 0.0% and ROIC -69.3%. Stock Foundry combines RZLT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +26.3%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +0.9% | -6.1% | +15.5% |
2026 Feb 12, 2026 | -37.5% | +5.8% | -9.4% | -28.5% |
2025 Nov 6, 2025 | +33.3% | +12.1% | +3.5% | +8.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RZLT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RZLT Max Drawdown
-87.20%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RZLT and SPY.
Company Overview
Rezolute, Inc.
NASDAQ Capital Market
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
- Leadership
- Nevan Charles Elam
- IPO Date
- Jan 14, 2013
- Employees
- 64
- Street Address
- 201 Redwood Shores Parkway
- Mailing
- Redwood City, CA, 94065
- Region
- Redwood City, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 206 4507
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 2.7
Growth
- Revenue
- 0.0%
- EPS
- +26.3%
- Free Cash Flow
- -20.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -64.8%
- ROIC
- -69.3%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 14.18
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.